Parker Geoffrey M. 4

What Happened

• Geoffrey M. Parker, Chief Financial Officer of Allogene Therapeutics (ALLO), received stock awards and completed a sell-to-cover share sale on Feb 2, 2026. He was granted a total of 691,552 restricted stock units (RSUs) in two awards (539,072 and 152,480 RSUs) reported at $0.00 (derivative awards). On the same day he sold 24,001 shares in open-market transactions at a weighted average price of $1.76 for proceeds of $42,242. The sale was to cover tax withholding and not a discretionary open-market trade.

Key Details

• Transaction date: Feb 2, 2026; Form 4 filed Feb 4, 2026 (timely — within the two-business-day window).
• Sale: 24,001 shares sold, weighted average price $1.76 (range $1.71–$1.83); total reported proceeds $42,242. (Footnote: multiple trades at different prices; detailed breakdown available on request.)
• Awards: 539,072 RSUs and 152,480 RSUs (total 691,552 RSUs) reported as derivative awards at $0.00; RSUs convert to one share each upon vesting.
• Shares owned after transaction: not specified in this filing.
• Notable footnotes:
  • F1: The sale was a mandated "sell-to-cover" to satisfy tax withholding — not a discretionary sale.
  • F2: Reported sale price is a weighted average; individual trades ranged $1.71–$1.83.
  • F3: Describes an option vesting schedule (25% on Feb 2, 2027, then monthly over 36 months) — pertains to stock option vesting language included in the filing materials.
  • F4: Confirms the awards are RSUs that vest in four equal annual installments beginning Feb 2, 2026.

Context

• The RSU grants are compensation-based awards that vest over time (per F4); they are not open-market purchases and are commonly used to align executive incentives with shareholders. The sale was a routine sell-to-cover for tax withholding, which is a common administrative transaction and does not by itself indicate a change in the insider’s view of the company.